BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 62 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2013. The put-call ratio across all filers is 3.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $7,312,000 | +64.9% | 1,155,104 | +14.9% | 7.86% | +80.4% |
| Q3 2016 | $4,433,000 | +55.3% | 1,005,104 | 0.0% | 4.36% | +47.4% |
| Q2 2016 | $2,854,000 | +79.2% | 1,005,104 | +78.5% | 2.96% | +113.9% |
| Q1 2016 | $1,593,000 | -71.4% | 562,943 | +50.6% | 1.38% | -12.1% |
| Q2 2015 | $5,579,000 | -64.6% | 373,686 | -78.6% | 1.57% | -56.6% |
| Q1 2015 | $15,752,000 | -25.7% | 1,744,356 | 0.0% | 3.63% | -37.8% |
| Q4 2014 | $21,211,000 | +24.3% | 1,744,356 | 0.0% | 5.84% | -23.9% |
| Q3 2014 | $17,060,000 | -23.3% | 1,744,356 | 0.0% | 7.67% | -35.5% |
| Q2 2014 | $22,241,000 | +20.5% | 1,744,356 | 0.0% | 11.89% | +23.9% |
| Q1 2014 | $18,455,000 | +38.4% | 1,744,356 | -0.6% | 9.59% | +33.7% |
| Q4 2013 | $13,333,000 | -16.0% | 1,754,356 | -19.5% | 7.18% | -18.2% |
| Q3 2013 | $15,875,000 | +910.5% | 2,180,656 | +115.2% | 8.77% | +651.2% |
| Q2 2013 | $1,571,000 | – | 1,013,442 | – | 1.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |